Psilocybin and depression: what the trials have reported

Over the past decade, psilocybin—the naturally occurring psychedelic compound found in certain fungi—has become a major focal point of modern psychiatric research. A series of clinical trials has investigated its potential to treat major depressive disorder and treatment-resistant depression, generating significant academic and public interest. This shift in scientific focus comes at a time when mental health professionals are urgently seeking new interventions for conditions that do not respond to conventional treatments. However, it is important to contextualise these developments within the law: in South Africa, psilocybin remains a Schedule 7 substance under the Medicines and Related Substances Act, meaning it is strictly prohibited and not approved for medical use. This article examines what the published trials have reported, looking at the reported effect sizes and the critical limitations of the current evidence base.

Early trials and the promise of rapid action

In early-stage and Phase II clinical trials, researchers at institutions such as Imperial College London and Johns Hopkins University have explored psilocybin-assisted therapy for depression. These studies generally involve administering the compound in a controlled clinical environment, accompanied by psychological preparation and integration support. A consistent finding across these trials is the rapid onset of antidepressant effects. Unlike conventional antidepressants, which can take several weeks to alleviate symptoms, some trial participants reported measurable improvements within days of the intervention.

Research suggests that this rapid action may be particularly relevant for individuals whose depression has not responded to standard treatments. Trials have generally been divided into two categories: those focusing on treatment-resistant depression (where patients have not improved after trying multiple standard treatments) and those examining broader major depressive disorder. While the results in both groups have been encouraging, researchers caution that early trials are primarily designed to test safety and初步 efficacy rather than to confirm clinical effectiveness.

Understanding reported effect sizes

In clinical research, 'effect size' is a statistical measure that helps us understand the magnitude of a treatment’s impact, rather than just whether it worked at all. Published trials of psilocybin for depression have frequently reported large initial effect sizes. For example, studies have often shown significant drops in standard depression rating scales, such as the Montgomery-Åsberg Depression Rating Scale (MADRS), within weeks of treatment. In some trials, a substantial proportion of participants entered remission, meaning their symptoms fell below the clinical threshold for depression.

While these figures are promising, researchers caution that large effect sizes in early trials must be interpreted carefully. In psychiatric research, it is common for early, small-scale studies to show inflated effect sizes that diminish when tested in larger, more diverse Phase III populations. Furthermore, because psilocybin is often administered alongside intensive psychological support, it is difficult to isolate how much of the improvement is due to the pharmacological action of the substance itself and how much is due to the therapeutic environment.

The blinding challenge and other limitations

Despite encouraging results, the body of evidence faces significant methodological limitations. One of the primary challenges is the 'blinding' problem. Because psilocybin is known to produce profound, often noticeable subjective effects, it is difficult to keep participants and researchers unaware of who received the active substance and who received the placebo. This lack of blinding can introduce expectation bias, where participants' belief in the treatment influences their reported outcomes. To address this, some trials have used low doses of psilocybin or other psychedelics as a comparator, though these methods have their own limitations.

Additionally, many published trials have involved small sample sizes and limited demographic diversity, which affects how generalisable the results are to the wider population. There is also a lack of long-term data on whether the antidepressant effects are sustained beyond a few months. While some participants maintain improvements over time, others relapse, highlighting the need for further research into the durability of the effects and the potential need for follow-up sessions.

Translating trials to South African policy

The transition from promising trial data to an approved medicine is a rigorous process. While the United States Food and Drug Administration (FDA) has previously granted 'breakthrough therapy' designations to psilocybin to expedite its development, it has not yet been approved for public use. In South Africa, the South African Health Products Regulatory Authority (SAHPRA) oversees such approvals. Currently, no psilocybin-based medicines are registered in the country, and the substance remains highly restricted.

For policy reform to be evidence-based, local regulators will look to larger, multi-site Phase III trials to confirm safety and efficacy. The precedent set by medical cannabis in South Africa—where patient access followed regulatory shifts after substantial international evidence accumulated—provides a framework for how such transitions might occur. However, until robust, large-scale data is available and reviewed by authorities like SAHPRA, psilocybin remains an experimental substance rather than an established treatment.